IJR News — today's news from every side

IJR News — today's news from every side

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

Radiopharm Theranostics reports 93% MRI concordanceHealth — Jul 21, 2026Radiopharm Theranostics reported in RAD101 Phase 2b a 93% concordance between PET and MRI in 30 evaluable patients with suspected brain metastases, along with preliminary 86% sensitivity; the company plans a U.S. Phase 3 pivotal trial in Q4 2026 as it advances toward a registrational program. In RAD204 Phase 1, Patient 1 achieved a durable partial response with up to 43% tumor reduction and progression-free status beyond seven months, while Patient 2 shows early signs of anti-tumor activity and remains on treatment.